Depomed Inc (DEPO)

16.93
0.32 1.90
NASDAQ : Health Care
Prev Close 17.25
Open 17.16
Day Low/High 16.73 / 17.30
52 Wk Low/High 12.25 / 33.16
Volume 585.21K
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 61.58M
Market Cap 971.13M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Board Revised as Perrigo Settles With Activist Investor Starboard

Board Revised as Perrigo Settles With Activist Investor Starboard

Starboard CEO Jeff Smith and two others are joining the board. The activist investor will also recommend two additional directors.

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Notable Thursday Option Activity: DEPO, OCN, X

Notable Thursday Option Activity: DEPO, OCN, X

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Depomed Inc , where a total volume of 8,605 contracts has been traded thus far today, a contract volume which is representative of approximately 860,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.6% of DEPO's average daily trading volume over the past month, of 1.8 million shares.

Dow's March to 20,000 Hits Another Snag as Crude Settles at Two-Week Low

Dow's March to 20,000 Hits Another Snag as Crude Settles at Two-Week Low

The Dow Jones Industrial Average's march to 20,000 hit another roadblock on the first trading day of the year as crude oil prices reversed course.

Dow's Attempt at 20,000 Fades as Crude Reverses Course

Dow's Attempt at 20,000 Fades as Crude Reverses Course

The Dow Jones Industrial Average's march to 20,000 proves a challenge in the new year as stocks more than halve earlier gains by Tuesday afternoon.

Stocks Ease Off Highs as Dow 20,000 Remains a Challenge

Stocks Ease Off Highs as Dow 20,000 Remains a Challenge

Stocks ease back from session highs, though remain in the green Tuesday morning, as the Dow's march to 20,000 proves a challenge in the new year.

Stock Futures Rise Ahead of First Trading Day of 2017

Stock Futures Rise Ahead of First Trading Day of 2017

Stock futures move higher Tuesday morning ahead of the first trading day of the new year.

First Week Of February 2017 Options Trading For Depomed (DEPO)

First Week Of February 2017 Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Ranking the Activists for Proxy Season 2016

Ranking the Activists for Proxy Season 2016

We recount the successes and failures of the biggest names in the activism game.

January 2017 Options Now Available For Depomed (DEPO)

January 2017 Options Now Available For Depomed (DEPO)

Investors in Depomed Inc saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.

Depomed Announces New CAMBIA® Formulation

Depomed Announces New CAMBIA® Formulation

- Formulation Removes Sweetener Aspartame -

Starboard DepoMed Director Deal Bolsters Sale Prospects

Starboard DepoMed Director Deal Bolsters Sale Prospects

The pain medication maker struck a deal with the fund managed by insurgent Jeff Smith to install a minority-slate of three dissident directors onto its board.

Drug Win for Depomed Could Be Hurdle for Starboard

Drug Win for Depomed Could Be Hurdle for Starboard

Increased chance for company's sale presents activist campaign with a steeper climb.

Depomed (DEPO) Closed Higher on Favorable Patent Ruling

Depomed (DEPO) Closed Higher on Favorable Patent Ruling

A New Jersey District Court has ruled in favor of Depomed's (DEPO) patents for its Nucynta drug franchise.

First Week of November 18th Options Trading For Depomed (DEPO)

First Week of November 18th Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Arbor and Purdue Seen as Likely Bidders for DepoMed

Arbor and Purdue Seen as Likely Bidders for DepoMed

The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.

Starboard Delivers Special Meeting Request To Depomed And Issues Letter To Depomed Shareholders

Starboard Delivers Special Meeting Request To Depomed And Issues Letter To Depomed Shareholders

Sets November 15, 2016 as the Date for the Special Meeting and Believes Depomed Has Notified Broadridge of a September 27, 2016 Record Date